Product Description: ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research[1].
Applications: Cancer-programmed cell death
Formula: C27H17Cl2NO5
References: [1]Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023 Nov 15;15(722):eadg6752.
CAS Number: 459789-75-4
Molecular Weight: 506.33
Compound Purity: 99.85
Research Area: Cancer
Solubility: DMSO : 69.5 mg/mL (ultrasonic;warming;heat to 60°C)